Reduced levels of complement C3 after peros administration of ornidazole in normal volunteers

 
Το τεκμήριο παρέχεται από τον φορέα :

Αποθετήριο :
Annals of Gastroenterology
δείτε την πρωτότυπη σελίδα τεκμηρίου
στον ιστότοπο του αποθετηρίου του φορέα για περισσότερες πληροφορίες και για να δείτε όλα τα ψηφιακά αρχεία του τεκμηρίου*
κοινοποιήστε το τεκμήριο




2007 (EL)

Reduced levels of complement C3 after peros administration of ornidazole in normal volunteers (EN)

Triantafillidis J., .
Barbatzas Ch.,
Konstantellou H.,
Hyphantis Th., .
Cheracakis P.,
Sklavena M.,
Driva G.,

SUMMARY Ornidazole, [a-(chloromethyl)-2-methyl-5-nitroimidazole- 1-ethanol], has recently been succesfully used in the treatment of active Crohn’s disease. Although the initial results were encouraging, the mode of its action is largely unknown. The present study was undertaken in order to see if ornidazole has any influence on the immune status, since immunity plays a significant role in the pathogenesis of inflammatory bowel disease, especially in Crohn’s disease. Ten healthy volunteers received orally 20 mg of ornidazole per Kg of body weight daily for eight days in two divided doses. The following immunological parameters were examined before, two and eight days after the administration of the drug: serum complement (C3 and C4), serum immunoglobulins (G, A and M), absolute number of peripheral lymphocytes, total B-lymphocytes (CD19+), total T lymphocytes (CD3), T helper-induced CD3+CD4 positive, T suppressor-cytotoxic (CD3+CD8 positive), Natural Killer cells (CD3-, CD16+, CD56+), Killer cell (CD8+CD58 positive) (lymphocyte activation index CD38) and subpopulation of B lymphocytes (CD20+ and CD5+). Other parameters examined were serum electrophoresis, number of platelets and number of white blood cells. The estimation of lymphocyte subpopulations was achieved by flow-cytometry technic in total peripheral blood using direct immunofluorence method with monoclonal antibodies of double color (double color immunofluorence). Ornidazole significantly reduced the levels of complement 3 after two and eight days of the peros administration, indicating that exclusive activation of the alternate pathway of complement activation occurs. However, other immune parameters showed no significant changes. It is concluded that ornidazole affects part of immune consistuents of normal volunteers if it is administered orally at a dose of 1000 mg per day for eight days. Further studies are needed in order to clarify the possible similar effects of the drug on the immune system of patients with inflammatory bowel disease. Key Words: Cellular Immunity, Humoral Immunity, Nitroimidazoles, Ornidazole, Metronidazole, Crohn’s disease, Inflammatory bowel disease (EN)

info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion


Αγγλική γλώσσα

2007-03-19


Hellenic Society of Gastroenterology (EN)

1792-7463
1108-7471
Annals of Gastroenterology; Volume 14, No 1 (2001) (EN)




*Η εύρυθμη και αδιάλειπτη λειτουργία των διαδικτυακών διευθύνσεων των συλλογών (ψηφιακό αρχείο, καρτέλα τεκμηρίου στο αποθετήριο) είναι αποκλειστική ευθύνη των αντίστοιχων Φορέων περιεχομένου.